Nicolas van Baren

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Hubing Shi, Willy Hugo, Xiangju Kong et al. · Cancer Discovery · 2013 · 986 citations · Full text

Medicine, Genetics, Oncology +17

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

Marie Marchand, Nicolas van Baren, P. Weynants et al. · International Journal of Cancer · 1999 · 786 citations

Life Sciences, Immunology, Oncology +17

Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann et al. · Immunity · 1997 · 772 citations · Full text

Life Sciences, Immunology, Oncology +16

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

Ivan Théate, Nicolas van Baren, Luc Pilotte et al. · Cancer Immunology Research · 2014 · 368 citations

Medicine, Immunology, Oncology +14

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman et al. · Journal of Clinical Oncology · 2016 · 308 citations

Life Sciences, Immunology, Oncology +17